Skip to main content

Table 1 HepG2 cells’ viability after treatment with doxorubicin (DOX), apigenin (A), hesperidin (H), hesperetin (HAGL), baicalin (B), baicalein (BAGL), cosmosiin (C), rhoifolin (R) and tested compounds treated simultaneously with doxorubicin. Data are presented as a mean ± SD % of a control

From: Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells

Concentration [μM]

Control

DOX

A

H

HAGL

B

BAGL

C

R

1

200

100

50

200

100

50

200

100

50

200

100

50

200

100

50

200

100

50

200

100

50

 

Mean ± SD %

 

100.04 ± 2.99

        

Compound alone

 

67.77 ± 2.44

45.66 ± 3.44*

50.55 ± 2.60*

67.64 ± 3.85*

66.55 ± 3.87*

75.85 ± 3.54*

82.65 ± 3.32*

81.64 ± 1.73*

97.24 ± 2.50

99.67 ± 3.45

81.50 ± 2.60*

87.74 ± 4.41*

90.52 ± 3.35*

74.04 ± 3.21*

77.82 ± 7.44*

81.73 ± 5.34*

100.81 ± 4.07

101.05 ± 2.13

99.87 ± 6.12

98.35 ± 7.08

99.13 ± 1.91

106.17 ± 9.50

Compound + DOX

  

32.75 ± 1.15♦

35.62 ± 0.73♦

52.31 ± 0.47♦

50.85 ± 2.28♦

62,23 ± 5.32♦

63.88 ± 3.55♦

78.96 ± 2.04

87.53 ± 3.97♦

86.55 ± 5.38♦

79.84 ± 2.65

80.79 ± 5.26

80.99 ± 3.46♦

68.79 ± 1.59

69.71 ± 3.20

69,11 ± 5.54

82.23 ± 5.08♦

76.77 ± 1.50♦

79.64 ± 2.18♦

73.02 ± 2.15♦

80.26 ± 1.75♦

87.03 ± 3.43♦

  1. * p ≤ 0.05 vs Control
  2. ♦ p ≤ 0.05 vs DOX